Evidence map›Paper›PMID 38058312›Full record

ArticleiScience2023

Specificity and efficiency of tamoxifen-mediated Cre induction is equivalent regardless of age.

Collyn M Kellogg, Kevin Pham, Sunghwan Ko, Jillian E J Cox, Adeline H Machalinski, Michael B Stout, Amanda L Sharpe, Michael J Beckstead, Ana J Chucair-Elliott, Sarah R Ocañas and 1 more

Abstract read
In one paragraph

Article in iScience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Collyn M KelloggGenes & Human Disease Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA.
Kevin PhamGenes & Human Disease Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA.
Sunghwan KoGenes & Human Disease Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA.
Jillian E J CoxGenes & Human Disease Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA.
Adeline H MachalinskiGenes & Human Disease Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA.
Michael B StoutAging & Metabolism Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA.
Amanda L SharpeDepartment of Pharmaceutical Sciences, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Michael J BecksteadAging & Metabolism Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA.
Ana J Chucair-ElliottGenes & Human Disease Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA.
Sarah R OcañasGenes & Human Disease Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA.
Willard M FreemanGenes & Human Disease Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA.

Funding

Targeted DNA Methylation and Mitochondrial Heteroplasmy CoreP30AG050911 · NIA · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI WILLARD M FREEMAN · 2015 to 2026
$13.9M
GEROSCIENCE TRAINING PROGRAM IN OKLAHOMAT32AG052363 · NIA · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI Benjamin Francis Miller, William Edmund Sonntag · 2017 to 2026
$3.6M
Sex divergence and cell specificity of age-related hippocampal DNA modificationsR01AG059430 · NIA · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI FREEMAN, WILLARD M · 2019 to 2023
$2.7M
Sex chromosomal regulation of hippocampal microglial activation with Alzheimer's disease and agingDP5OD033443 · OD · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI OCANAS, SARAH RENEE · 2022 to 2025
$2.2M
Ventral tegmental area involvement in Alzheimer's pathologyR21AG072811 · NIA · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI BECKSTEAD, MICHAEL J · 2021 to 2021
$481k
Epigenetic regulation of sexually divergent neuroinflammation with brain aging and Alzheimer's diseaseF31AG064861 · NIA · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI OCANAS, SARAH RENEE · 2019 to 2021
$94k
Regulation of Microglial Function by Major Histocompatibility Complex I in Aging and Alzheimer's DiseaseF30AG087705 · NIA · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI KELLOGG, COLLYN MICHAEL · 2024 to 2024
$44k
Plasticity of GABA input to VTA dopamine neurons in opioid use disordersI01BX005396 · VA · OKLAHOMA CITY VA MEDICAL CENTER · PI BECKSTEAD, MICHAEL J · 2022 to 2025
–
BLRD Research Career Scientist Award ApplicationIK6BX006033 · VA · OKLAHOMA CITY VA MEDICAL CENTER · PI FREEMAN, WILLARD M · 2022 to 2025
–
Dynamics of the brain epigenome with agingI01BX003906 · VA · OKLAHOMA CITY VA MEDICAL CENTER · PI FREEMAN, WILLARD M · 2018 to 2021
–
BLRD VA I01 BX003906BLRD VA I01 BX005396BLRD VA I01 BX005592BLRD VA IK6 BX006033NIA NIH HHS F30 AG087705NIA NIH HHS F31 AG064861NIA NIH HHS P30 AG050911NIA NIH HHS R01 AG059430NIA NIH HHS R21 AG072811NIA NIH HHS T32 AG052363NIH HHS DP5 OD033443
6 · The paper itself

Abstract

Temporally controlling Cre recombination through tamoxifen (Tam) induction has many advantages for biomedical research. Most studies report early post-natal/juvenile (<2 m.o.) Tam induction, but age-related neurodegeneration and aging studies can require Cre induction in older mice (>12 m.o.). While anecdotally reported as problematic, there are no published comparisons of Tam-mediated Cre induction at early and late ages. Here, microglial-specific

Indexed as

Biological sciencesBiological sciences research methodologiesBiology experimental methodsGenomicsNatural sciences

Identifiers

PMID38058312
PMCPMC10696116

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.